Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-002344-84 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this first-in human study is to demonstrate systemic and local tolerability and investigate pharmacokinetics of LFX453 after multiple topical applications in healthy subjects.
The current study has been designed with three distinct parts. Part 1 focuses on safety and tolerability of once daily application on the back, prior to moving forward and assessing the safety and tolerability in more sensitive treatment areas in Part 2 or twice daily application in Part 3.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1: LFX453/placebo | Experimental | once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2 |
|
| Part 2 groupA: LFX453/placebo | Experimental | once daily: LFX453 cream 1 / Placebo 1 |
|
| Part 2 groupB: LFX453/placebo | Experimental | once daily: LFX453 cream 2 / Placebo 2 |
|
| Part 2 groupC: LFX453/LFX453 | Experimental | once daily: LFX453 cream 1 / LFX453 cream 2 |
|
| Part 2 groupD: Imiquimod | Other | once daily: imiquimod cream |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LFX453 H1 | Drug | LFX453 high dose cream 1 |
|
| Measure | Description | Time Frame |
|---|---|---|
| General safety (number of subjects with adverse events) | Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events and death. | 14 days |
| Local skin tolerability (tolerability score) | Summarized statistics on 5-point scale tolerability scores over 14 days of treatment. | 14 days |
| Measure | Description | Time Frame |
|---|---|---|
| All parts: Amount (ng/mL) of LFX453 in plasma | Evaluate systemic steady state pharmacokinetics in human after topical administration of LFX453. | 14 days |
| Part 1 and 2: LFX453 concentrations (ng/g) in the skin |
Not provided
Inclusion Criteria:
Exclusion Criteria:
History of serious allergic reaction to any drug.
History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
History of any atopic dermatitis (only within the last 2 years), autoimmune disease, psoriasis or erythema multiforme.
Presence of skin disease (e.g. warts) or skin features on treatment areas that may affect local tolerability or the ability of the investigator to evaluate local tolerability.
History of heart failure, left ventricular dysfunction or known family history or known presence of long QT syndrome.
A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening or baseline:
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | Mid Glamorgan | CF484DR | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D000077271 | Imiquimod |
| ID | Term |
|---|---|
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Part 3: LFX453/placebo | Experimental | twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2 |
|
| LFX453 L1 | Drug | LFX453 low dose cream 1 |
|
| LFX453 H2 | Drug | LFX453 high dose cream 2 |
|
| LFX453 L2 | Drug | LFX453 low dose cream 2 |
|
| Imiquimod | Drug | Imiquimod cream |
|
| Placebo 1 | Drug | Placebo cream 1 |
|
| Placebo 2 | Drug | Placebo cream 2 |
|
LFX453 analyzed in skin.
| Day 14 and between days 18-21 |
| All parts: LFX453 concentration (ng/mL) in urine | LFX453 analyzed in urine. | Day 14 |
| D006571 | Heterocyclic Compounds |